ROYALTY PHARMA PLC CLASS A (RPRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RPRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RPRX | Lead Independent Director; Chair | 67 | ["Former Chair, Biotechnology Innovation Organization (BIO)","Chair of BIO’s Board of Directors for a two-year term (2023-2025)","President and CEO of Global Blood Therapeutics, Inc. (June 2014 to October 2022)","Executive Vice President of research and development and technical operations at Onyx Pharmaceuticals, Inc. (February 2010 to August 2012)","President, CEO, and Chairman of Nuvelo, Inc. (2001 to January 2009)","Senior Vice President of development at Theravance, Inc. (1998 to 2001)","Experience at Genentech, Inc. in senior management positions","B.A. in molecular biology from Haverford College","M.D. from Yale Medical School","Completed residency in internal medicine and fellowship in cardiology at Massachusetts General Hospital","Experience on boards of other public healthcare companies"] | ["Nominating and Corporate Governance Committee (Chair)","Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Love served as BIO's Chair of its Board of Directors for a two-year term (2023-2025). Previously, Dr. Love served as president and chief executive officer of Global Blood Therapeutics, Inc. from June 2014 to October 2022. From February 2010 to August 2012, he served as executive vice president, research and development and technical operations, at Onyx Pharmaceuticals, Inc. Prior to Onyx, from 2001 to January 2009, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc. Prior to that, he served as senior vice president, development, at Theravance, Inc. from 1998 to 2001. Previously, he spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentech's Product Development Committee. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital. Dr. Love was selected to serve on our Board because of his more than 20 years of leadership and management experience in the biopharmaceutical industry, including BIO, Global Blood Therapeutics, Inc. and Onyx Pharmaceuticals, Inc., in addition to his prior experience as a practicing physician. Dr. Love also has notable experience on the boards of other public healthcare companies. He brings both strong business expertise, experience as a CEO of a global healthcare company, and knowledge of patient perspectives to our Board.